Citations

Showing 10 of 108104 citations.

What Are the Interactions Between the Midbrain Dopamine System in Pain?
Benarroch, Eduardo, Benarroch, Eduardo

Mayo Clinic

Neurology | February 15, 2022 | Volume: 98 | Issue: 7 | Pages: 274-278

10.1212/wnl.0000000000013253 | PMID 35165154 Get It

Chaput tubercle avulsion: Sonographic appearance and diagnosis
Shrestha, Roman , Dahiya, Nirvikar , Alli, Adebisi , Long, Jeremiah R. , Flug, Jonathan A.

Mayo Clinic

PM&R | February 15, 2022 | Volume: 14 | Issue: 4 | Pages: 515-517

10.1002/pmrj.12786 | PMID 35166039 Get It

The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease
Liang, Minrui , Matteson, Eric L. , Abril, Andy , Distler, Jörg H. W.

Mayo Clinic

Therapeutic Advances in Musculoskeletal Disease | February 15, 2022 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/1759720x221074457 | PMID 35186127 Get It

The major pulmonary complication of rheumatoid arthritis (RA) is interstitial lung disease (ILD), which causes significant morbidity and mortality and influences the natural course of disease. Recent advances in the management of arthritis have improved patient outcomes. However, exceptionally high medical needs still remain for effective therapies for the patients with ILD in RA. Better understanding of the shared and distinct pathophysiology of fibrotic diseases led to the development of novel antifibrotic agents such as nintedanib and pirfenidone. The further stratification analysis of the phase III INBUILD trial demonstrated beneficial effects of nintedanib in RA-ILD with a progressive phenotype by reducing the rate of decline in forced vital capacity (FVC) over 52 weeks by 60%. Pirfenidone is another antifibrotic agent currently under phase II clinical study (TRAIL1) aiming to evaluate its effects for RA-ILD. This review provides an overview of state-of-the-art pathogenesis and the current therapeutic options for RA-ILD, with a focus on antifibrotic strategies.
FollowTheSutures: Piloting a new way to administer onabotulinumtoxinA for chronic migraine
Stovner, Lars Jacob , Hagen, Knut , Burstein, Rami , Tronvik, Erling , Gravdahl, Gøril Bruvik , Dodick, David W.

Mayo Clinic

Cephalalgia | February 15, 2022 | Volume: 42 | Issue: 7 | Pages: 590-597

10.1177/03331024211067775 | PMID 35166150 Get It

Background Anatomical and experimental data indicate that onabotulinimtoxin A could be more efficient and cost-effective for treating chronic migraine with injections targeting the cranial sutures, where collaterals from the meninges penetrate the skull. Methods A new injection paradigm (FollowTheSutures) was tested for safety, tolerability and feasibility in a Phase II, open-label, non-controlled, single-center pilot study. Ninety units of onabotulinimtoxin A (Botox®), were injected in 18 sites over the area of the cranial sutures. Adverse events and potential beneficial effects were recorded in a headache diary at least 4 weeks before, and for 12 weeks after the injections. A higher dilution than normal of onabotulinimtoxin A was used to get better diffusion. Results Nineteen (of 20 included) women with chronic migraine received the injections and were evaluable. There was only one treatment-related adverse event (reduced power of chewing for some weeks). Otherwise, the procedure was overall well tolerated. Patients improved on most efficacy parameters after the injections. There was little or no effect on glabellar or forehead lines. Conclusions The protocol was safe and well tolerated. Lower risk of unblinding due to the absence of cosmetic effects should make the injection procedure well suited for a large, randomized, placebo-controlled study. If efficacy is confirmed, it will be markedly less costly than the standard procedure. Trial registration: EUDRACT (2017-002516-13), ClinicalTrials.gov (NCT03543254).
A Critical Analysis of Reporting in Systematic Reviews and Meta-Analyses in the Peyronie’s Disease Literature
Bole, Raevti , Gottlich, Harrison Chase, Ziegelmann, Matthew , Corrigan, Dillon , Levine, Laurence A. , Mulhall, John P. , Ziegelmann, Matthew J, Bajic, Petar

Mayo Clinic

The Journal of Sexual Medicine | February 15, 2022 | Volume: 19 | Issue: 4 | Pages: 629-640

10.1016/j.jsxm.2022.01.008 | PMID 35177375 Get It

ABSTRACTBackgroundDespite an increasing number of publications on Peyronie’s disease (PD), evidence-based clinical decision-making remains challenging due to the small number of well-designed clinical trials.AimTo perform a critical analysis of reporting quality in PD systematic reviews (SR) and meta-analyses (MA).MethodsStudy protocol registration was performed on the Open Science Framework platform. In January 2021, a systematic electronic search of the Medline/PubMed, Embase, Ovid, Scopus, Joanne Briggs Institute, and Cochrane databases was performed. Search terms included “Peyronie’s disease” and “systematic review OR meta-analysis OR meta-analysis.” Eligibility criteria were English-language, relevance to PD and specification of “systematic review” or “meta-analysis” in the title or abstract. Oxford Center for Evidence-Based Medicine levels of evidence were used to classify original studies reviewed within each publication. Risk of bias was assessed using the ROBIS tool. Data were tabulated and reported as means with standard deviation, median with interquartile range and t-testing as appropriate. Strength of association between variables was calculated using Pearson correlation coefficient. Statistical analyses were performed on RStudio (version 1.4.1106).OutcomesOutcomes included review type, level of evidence, authorship, journal, publication date, “A MeaSurement Tool to Assess systematic Reviews” (AMSTAR-2) score and “Preferred Reporting Items for Systematic Reviews and Meta-Analyses” (PRISMA) score.ResultsFrom 1974 to 2021, 340 articles were identified. After review, 17 full length articles were included. Thirteen were SR, 2 MA and 2 was combined. Significant heterogeneity was seen in evidence level of included studies. There was median 54% adherence to AMSTAR-2 criteria and 74% adherence to PRISMA criteria. Overall AMSTAR-2 confidence rating was Critically Low in 11 of 17 studies. Correlation analysis revealed very high positive association between AMSTAR 2 and PRISMA adherence (+0.95). ROBIS revealed “High” concern regarding methods used to collect data and appraise 12/17 studies (71%), and “High” concern regarding synthesis and findings in 8 of 17 studies (47%).Clinical ImplicationsMany SR include markedly heterogenous levels of evidence and fail to meet accepted methodological criteria for reporting.Strengths and LimitationsMain strengths include extensive literature review and analysis of standardized study reporting. One limitation is that aggregate scoring of AMSTAR-2 and PRISMA is not intended as primary method of quality assessment; however effect was minimized by reporting critical domains, overall quality assessments and specifics on globally poorly reported domains.ConclusionMore high quality randomized controlled PD trials are necessary; SR and MA should focus on these studies alone.
Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma
Kuruvilla, John , Bijou, Fontanet , Santoro, Armando , Boccomini, Carola , Kenkre, Vaishalee P. , Isufi, Iris, Andorsky, David , Klein, Leonard M., Greenwald, Daniel, Sangha, Randeep, Shen, Frank, Hagner, Patrick R. , Dobmeyer, Juergen, Gong, Nian , Uttamsingh, Shailaja, Pourdehnad, Michael , Kuruvilla, John , Ribrag, Vincent , Santoro, Armando , Nastoupil, Loretta J. , Chavez, Julio C , Witzig, Thomas E. , Flinn, Ian W. , Corradini, Paolo , Li, Yan , Gong, Nian

Mayo Clinic

eJHaem | February 15, 2022 | Volume: 3 | Issue: 2 | Pages: 394-405

10.1002/jha2.394 | PMID 35846031 Get It

AbstractThe multicenter, phase Ib CC‐122‐DLBCL‐001 dose‐expansion study (NCT02031419) explored the cereblon E3 ligase modulator (CELMoD) agent avadomide (CC‐122) plus rituximab in patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) or follicular lymphoma (FL). Patients received avadomide 3 mg/day 5 days on/2 days off plus rituximab 375 mg/m2 on day 8 of cycle 1, day 1 of cycles 2 through 6, and day 1 of every third subsequent cycle for 2 years. Primary endpoints were safety and tolerability; preliminary efficacy was a secondary endpoint. A total of 68 patients were enrolled (DLBCL [n = 27], FL [n = 41; 31 lenalidomide‐naïve, 10 lenalidomide‐treated]). Median age was 62 years (range, 33–84 years), and patients had received a median of 3 (range, 1–8) prior regimens. Among patients with DLBCL, 66.7% had primary refractory disease (partial response or less to initial therapy). Among patients with FL, 65.9% were rituximab‐refractory at study entry and 10.0% were lenalidomide‐refractory. The most common any‐grade avadomide‐related adverse events (AEs) were neutropenia (63.2%), infections/infestations (23.5%), fatigue (22.1%), and diarrhea (19.1%). The most common grade 3/4 avadomide‐related AEs were neutropenia (55.9%) infections/infestations (8.8%), and febrile neutropenia (7.4%). In patients with DLBCL, overall response rate (ORR) was 40.7% and median duration of response (mDOR) was 8.0 months. In patients with FL, ORR was 80.5% and mDOR was 27.6 months; response rates were similar in lenalidomide‐naïve and ‐treated patients. Avadomide plus rituximab was well tolerated, and preliminary antitumor activity was observed in patients with R/R DLBCL and FL, including subgroups with typically poor outcomes. These results support further investigation of novel CELMoD agents in combination with rituximab in R/R DLBCL and FL.
Personalizing Deep Brain Stimulation Using Advanced Imaging Sequences
Neudorfer, Clemens , Kroneberg, Daniel , Al‐Fatly, Bassam , Goede, Lukas L. , Kübler, Dorothee , Faust, Katharina , Rienen, Ursula van , Picht, Thomas , Middlebrooks, Erik H. , Kühn, Andrea A. , Schneider, Gerd‐Helge , Horn, Andreas , Goede, Lukas , van Rienen, Ursula , Horn, Andreas , Middlebrooks, Erik H , Kühn, Andrea A , Tietze, Anna , Herrington, Todd M.

Mayo Clinic

Annals of Neurology | February 15, 2022 | Volume: 91 | Issue: 5 | Pages: 613-628

10.1002/ana.26326 | PMID 35165921 Get It

Objective With a growing appreciation for interindividual anatomical variability and patient‐specific brain connectivity, advanced imaging sequences offer the opportunity to directly visualize anatomical targets for deep brain stimulation (DBS). The lack of quantitative evidence demonstrating their clinical utility, however, has hindered their broad implementation in clinical practice. Methods Using fast gray matter acquisition T1 inversion recovery (FGATIR) sequences, the present study identified a thalamic hypointensity that holds promise as a visual marker in DBS. To validate the clinical utility of the identified hypointensity, we retrospectively analyzed 65 patients (26 female, mean age = 69.1 ± 12.7 years) who underwent DBS in the treatment of essential tremor. We characterized its neuroanatomical substrates and evaluated the hypointensity's ability to predict clinical outcome using stimulation volume modeling and voxelwise mapping. Finally, we determined whether the hypointensity marker could predict symptom improvement on a patient‐specific level. Results Anatomical characterization suggested that the identified hypointensity constituted the terminal part of the dentatorubrothalamic tract. Overlap between DBS stimulation volumes and the hypointensity in standard space significantly correlated with tremor improvement ( R 2 = 0.16, p = 0.017) and distance to hotspots previously reported in the literature ( R 2 = 0.49, p = 7.9e‐4). In contrast, the amount of variance explained by other anatomical atlas structures was reduced. When accounting for interindividual neuroanatomical variability, the predictive power of the hypointensity increased further ( R 2 = 0.37, p = 0.002). Interpretation Our findings introduce and validate a novel imaging‐based marker attainable from FGATIR sequences that has the potential to personalize and inform targeting and programming in DBS for essential tremor. ANN NEUROL 2022;91:613–628
Pathogenesis and Staging of Craniovertebral Tuberculosis: Radiographic Evaluation, Classification, and Natural History
Chaudhary, Kshitij , Pennington, Zach , Rathod, Ashok, Laheri, Vinod, Bapat, Mihir , Sciubba, Daniel M. , Suratwala, Sanjeev J. , Pennington, Zach

Mayo Clinic

Global Spine Journal | February 15, 2022 | Volume: 13 | Issue: 8 | Pages: 2155-2167

10.1177/21925682221074671 | PMID 35164582 Get It

Study Design Retrospective cohort. Objective To radiographically evaluate Craniovertebral junction (CVJ) tuberculosis infection pathogenesis and to propose a modification to the Lifeso classification. Methods A cohort of patients with radiologically or microbiologically identified CVJ tuberculosis treated at a single tertiary referral center in a TB endemic area was queried for characteristics about clinical presentation, treatment, and radiographic evidence of bone destruction and abscess formation were included. Disease was classified according to the Lifeso grading system and bony lesions were classified as either type 1 (preservation of underlying structure) or type 2 (damage of underlying structure). Results 52 patients were identified (mean age 28.5 ± 13.4yr, 48% male; 14% with a prior history of tuberculosis). All presented with neck pain at presentation, 29% with rotatory pain, and 37% with myelopathy. Comparison by Lifeso type showed Lifeso III lesions had longer symptom durations ( P = .03) and more commonly had periarticular or predental abscess formation ( P < .05), spinal cord compression ( P < .01), and more commonly involved the C2 body and atlanto-dental joint. Underlying bony destruction was more common for lesions of the lateral atlantoaxial joints and atlanto-dental joints in Lifeso III cases than in either Lifeso I or II (all P < .05). Conclusions The radiologic findings of the present series suggest CVJ TB infection may originate in the periarticular fascia with subsequent invasion into the adjacent atlanto-dental and lateral atlantoaxial joints in later disease. To reflect this proposed etiology, we present a modified Lifeso classification to describe the radiologic pathogenesis of CVJ TB.
The Most Highly Cited Publications on Basketball Originate From English‐Speaking Countries, Are Published After 2000, Are Focused on Medicine‐Related Topics, and Are Level III Evidence
Griffin, Zachary D., McQuivey, Kade S. , Arthur, Jaymeson R. , Chhabra, Anikar , Chhabra, Anikar , Griffin, Zachary D., Pollock, Jordan Riley , Moore, M. Lane

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | February 14, 2022 | Volume: 4 | Issue: 3 | Pages: No page available

10.1016/j.asmr.2021.12.020 | PMID 35747657 Get It

Purpose To identify the 50 most highly cited research publications in the sport of basketball. Methods Using the Clarivate Analytics Web of Knowledge database and the search term “basketball”, we identified 2,704 articles. These articles were filtered by the total number of citations and the top 50 most cited articles with a central focus on basketball were selected for this analysis. For each article, we further identified and analyzed author name, publication year, country of origin, journal name, article type, main research topic area, competitive level, gender of study population, and the level of evidence. Results Medicine‐related topics, particularly those involving knee injuries, are more common than nonmedical topics (coaching, sports psychology etc.) among the highest cited articles. Articles originated from 13 different countries, with 48% originating in the United States. Only four authors had more than one article included in the top 50 most cited articles. Conclusion A majority of the top 50 research articles were from English‐speaking countries, published after 2000, primarily focused on medicine‐related topics, and were Level III evidence. Publications examining knee injuries were the most highly cited and appear to be of high interest to current investigators. The prestige of an author’s name appeared to be less influential to the number of citations. Clinical Relevance The top 50 most cited articles list will provide researchers, medical students, residents, and fellows with a foundational list of the most important and influential academic contributions to the basketball literature.
Artificial Intelligence and Cardiovascular Genetics
Krittanawong, Chayakrit , Johnson, Kipp W. , Choi, Edward , Kaplin, Scott , Venner, Eric , Murugan, Mullai , Glicksberg, Benjamin S. , Amos, Christopher I. , Schatz, Michael C. , Tang, W.H. Wilson , Glicksberg, Benjamin , Amos, Christopher I , Schatz, Michael C , Tang, W H Wilson , Venner, Eric , Wang, Zhen

Mayo Clinic

Life | February 14, 2022 | Volume: 12 | Issue: 2 | Pages: 279

10.3390/life12020279 | PMID 35207566 Get It

Polygenic diseases, which are genetic disorders caused by the combined action of multiple genes, pose unique and significant challenges for the diagnosis and management of affected patients. A major goal of cardiovascular medicine has been to understand how genetic variation leads to the clinical heterogeneity seen in polygenic cardiovascular diseases (CVDs). Recent advances and emerging technologies in artificial intelligence (AI), coupled with the ever-increasing availability of next generation sequencing (NGS) technologies, now provide researchers with unprecedented possibilities for dynamic and complex biological genomic analyses. Combining these technologies may lead to a deeper understanding of heterogeneous polygenic CVDs, better prognostic guidance, and, ultimately, greater personalized medicine. Advances will likely be achieved through increasingly frequent and robust genomic characterization of patients, as well the integration of genomic data with other clinical data, such as cardiac imaging, coronary angiography, and clinical biomarkers. This review discusses the current opportunities and limitations of genomics; provides a brief overview of AI; and identifies the current applications, limitations, and future directions of AI in genomics.